Do Variants Associated with Susceptibility to Pancreatic Cancer and Type 2 Diabetes Reciprocally Affect Risk?

被引:12
作者
Wu, Lang [1 ,2 ]
Rabe, Kari G. [1 ]
Petersen, Gloria M. [1 ]
机构
[1] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55902 USA
[2] Mayo Clin, Ctr Clin & Translat Sci, Rochester, MN USA
来源
PLOS ONE | 2015年 / 10卷 / 02期
关键词
GENOME-WIDE ASSOCIATION; GENETIC SUSCEPTIBILITY; LOCI; METAANALYSIS; GLUCOSE; MELLITUS; MTNR1B; KCNQ1;
D O I
10.1371/journal.pone.0117230
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives Although type 2 diabetes mellitus is a known risk factor for pancreatic cancer, the existence of shared genetic susceptibility is largely unknown. We evaluated whether any reported genetic risk variants of either disease found by genome-wide association studies reciprocally confer susceptibility. Methods Data that were generated in previous genome-wide association studies (GENEVA Type 2 Diabetes; PanScan) were obtained through the National Institutes of Health database of Genotypes and Phenotypes (dbGaP). Using the PanScan datasets, we tested for association of 38 variants within 37 genomic regions known to be susceptibility factors for type 2 diabetes. We further examined whether type 2 diabetes variants predispose to pancreatic cancer risk stratified by diabetes status. Correspondingly, we examined the association of fourteen pancreatic cancer susceptibility variants within eight genomic regions in the GENEVA Type 2 Diabetes dataset. Results Four plausible associations of diabetes variants and pancreatic cancer risk were detected at a significance threshold of p = 0.05, and one pancreatic cancer susceptibility variant was associated with diabetes risk at threshold of p = 0.05, but none remained significant after correction for multiple comparisons. Conclusion Currently identified GWAS susceptibility variants are unlikely to explain the potential shared genetic etiology between Type 2 diabetes and pancreatic cancer.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Type 2 diabetes risk variants and colorectal cancer risk: the Multiethnic Cohort and PAGE studies
    Cheng, Iona
    Caberto, Christian P.
    Lum-Jones, Annette
    Seifried, Ann
    Wilkens, Lynne R.
    Schumacher, Fredrick R.
    Monroe, Kristine R.
    Lim, Unhee
    Tiirikainen, Maarit
    Kolonel, Laurence N.
    Henderson, Brian E.
    Stram, Daniel O.
    Haiman, Christopher A.
    Le Marchand, Loic
    GUT, 2011, 60 (12) : 1703 - 1711
  • [22] Role of Established Type 2 Diabetes-Susceptibility Genetic Variants in a High Prevalence American Indian Population
    Hanson, Robert L.
    Rong, Rong
    Kobes, Sayuko
    Muller, Yunhua Li
    Weil, E. Jennifer
    Curtis, Jeffrey M.
    Nelson, Robert G.
    Baier, Leslie J.
    DIABETES, 2015, 64 (07) : 2646 - 2657
  • [23] Functional mechanisms for type 2 diabetes-associated genetic variants
    Zhu, Xiao-Wei
    Deng, Fei-Yan
    Wu, Long-Fei
    Tang, Zai-Xiang
    Lei, Shu-Feng
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (04) : 497 - 501
  • [24] A role for coding functional variants in HNF4A in type 2 diabetes susceptibility
    Jafar-Mohammadi, B.
    Groves, C. J.
    Gjesing, A. P.
    Herrera, B. M.
    Winckler, W.
    Stringham, H. M.
    Morris, A. P.
    Lauritzen, T.
    Doney, A. S. F.
    Morris, A. D.
    Weedon, M. N.
    Swift, A. J.
    Kuusisto, J.
    Laakso, M.
    Altshuler, D.
    Hattersley, A. T.
    Collins, F. S.
    Boehnke, M.
    Hansen, T.
    Pedersen, O.
    Palmer, C. N. A.
    Frayling, T. M.
    Gloyn, A. L.
    McCarthy, M. I.
    DIABETOLOGIA, 2011, 54 (01) : 111 - 119
  • [25] Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes
    Tseng, Chin-Hsiao
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2014, 63 (08): : 1049 - 1055
  • [26] Polygenic Risk Variants for Type 2 Diabetes Susceptibility Modify Age at Diagnosis in Monogenic HNF1A Diabetes
    Lango Allen, Hana
    Johansson, Stefan
    Ellard, Sian
    Shields, Beverley
    Hertel, Jens K.
    Raeder, Helge
    Colclough, Kevin
    Molven, Anders
    Frayling, Timothy M.
    Njolstad, Pai R.
    Hattersley, Andrew T.
    Weedon, Michael N.
    DIABETES, 2010, 59 (01) : 266 - 271
  • [27] The Role of Type 2 Diabetes in Pancreatic Cancer
    George, Sheeba
    Jean-Baptiste, Wilford
    Ali, Amina Yusuf
    Inyang, Bithaiah
    Koshy, Feeba Sam
    George, Kitty
    Poudel, Prakar
    Chalasani, Roopa
    Goonathilake, Mastiyage R.
    Waqar, Sara
    Mohammed, Lubna
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [28] Treatment of type 2 diabetes mellitus and risk of pancreatic cancer
    Olakowska, Edyta
    Olakowski, Marek
    ENDOKRYNOLOGIA POLSKA, 2021, 72 (04) : 395 - 401
  • [29] IRS1 gene variants, dysglycaemic metabolic changes and type-2 diabetes risk
    Yiannakouris, N.
    Cooper, J. A.
    Shah, S.
    Drenos, F.
    Ireland, H. A.
    Stephens, J. W.
    Li, K-W
    Elkeles, R.
    Godsland, I. F.
    Kivimaki, M.
    Hingorani, A. D.
    Kumari, M.
    Talmud, P. J.
    Humphries, S. E.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2012, 22 (12) : 1024 - 1030
  • [30] Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis
    Soranna, Davide
    Scotti, Lorenza
    Zambon, Antonella
    Bosetti, Cristina
    Grassi, Guido
    Catapano, Alberico
    La Vecchia, Carlo
    Mancia, Giuseppe
    Corrao, Giovanni
    ONCOLOGIST, 2012, 17 (06) : 813 - 822